Drug interactions
Palifermin + Regorafenib
Severity: Minor
Palifermin and Regorafenib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Palifermin is given to reduce mucositis caused by cytotoxic chemotherapy, and its timing relative to antineoplastics matters because it may stimulate epithelial cell growth. Giving it close to chemotherapy worsened mucositis in labeling data. This concern is not established for oral kinase inhibitors like regorafenib, which is taken continuously, so the interaction is largely theoretical.
What this interaction means in plain words
Palifermin and Regorafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Palifermin belongs to Miscellaneous; Regorafenib belongs to Oncology.
Why it happens
Palifermin stimulates epithelial proliferation, which may increase sensitivity to cytotoxic agents; no specific mechanism with regorafenib is established.
What to do
Palifermin is not indicated with regorafenib, so use it only for approved settings. If given, monitor for oral mucositis and skin toxicity.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Palifermin and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Regorafenib
Other interactions of Palifermin
Frequently asked questions
Can I take Palifermin with Regorafenib?
MediHelp rates the interaction as minor. Palifermin and Regorafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Palifermin is given to reduce mucositis caused by cytotoxic chemotherapy, and its timing relative to antineoplastics matters because it may stimulate epithelial cell growth. Giving it close to chemotherapy worsened mucositis in labeling data. This concern is not established for oral kinase inhibitors like regorafenib, which is taken continuously, so the interaction is largely theoretical.
How serious is the interaction between Palifermin and Regorafenib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Palifermin is not indicated with regorafenib, so use it only for approved settings. If given, monitor for oral mucositis and skin toxicity.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
